The stock of Xencor Inc (NASDAQ:XNCR) is a huge mover today! The stock decreased 4.00% or $0.99 during the last trading session, hitting $23.73. About 338,359 shares traded hands or 31.15% up from the average. Xencor Inc (NASDAQ:XNCR) has risen 108.78% since March 2, 2016 and is uptrending. It has outperformed by 100.53% the S&P500.
The move comes after 7 months negative chart setup for the $977.27 million company. It was reported on Oct, 6 by Barchart.com. We have $22.07 PT which if reached, will make NASDAQ:XNCR worth $68.41M less.
Analysts await Xencor Inc (NASDAQ:XNCR) to report earnings on November, 1. They expect $-0.08 EPS, up 68.00% or $0.17 from last year’s $-0.25 per share. After $1.13 actual EPS reported by Xencor Inc for the previous quarter, Wall Street now forecasts -107.08% negative EPS growth.
Xencor Inc (NASDAQ:XNCR) Ratings Coverage
Out of 5 analysts covering Xencor (NASDAQ:XNCR), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Xencor has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Xencor Inc (NASDAQ:XNCR) has “Buy” rating given on Tuesday, December 22 by Canaccord Genuity. The stock of Xencor Inc (NASDAQ:XNCR) earned “Overweight” rating by Piper Jaffray on Tuesday, October 4. The stock has “Hold” rating given by Zacks on Saturday, August 8. The firm earned “Hold” rating on Friday, September 4 by Zacks. The stock of Xencor Inc (NASDAQ:XNCR) has “Outperform” rating given on Tuesday, March 8 by Leerink Swann. The stock of Xencor Inc (NASDAQ:XNCR) has “Buy” rating given on Wednesday, August 5 by MLV. The stock of Xencor Inc (NASDAQ:XNCR) earned “Outperform” rating by Leerink Swann on Thursday, September 17.
According to Zacks Investment Research, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.”
Insitutional Activity: The institutional sentiment increased to 1.64 in 2016 Q2. Its up 0.40, from 1.24 in 2016Q1. The ratio is positive, as 10 funds sold all Xencor Inc shares owned while 23 reduced positions. 13 funds bought stakes while 41 increased positions. They now own 27.63 million shares or 4.30% less from 28.87 million shares in 2016Q1.
Oxford Asset Management owns 367,101 shares or 0.29% of their US portfolio. Morgan Stanley holds 0% or 39,156 shares in its portfolio. Aqr Capital Management Lc last reported 0% of its portfolio in the stock. Manufacturers Life The holds 0% or 22,735 shares in its portfolio. Vident Investment Advisory has invested 0.13% of its portfolio in Xencor Inc (NASDAQ:XNCR). Oppenheimer & Company has 0.01% invested in the company for 14,506 shares. Blackrock Limited holds 0% or 6,824 shares in its portfolio. New York State Common Retirement Fund has invested 0% of its portfolio in Xencor Inc (NASDAQ:XNCR). Adage Prtn Grp Inc Ltd Liability accumulated 0.01% or 100,000 shares. Qvt Finance L P holds 0.51% or 386,925 shares in its portfolio. Ubs Asset Management Americas Inc accumulated 0% or 14,800 shares. Ecor1 Capital Ltd Liability Co accumulated 1.26% or 168,000 shares. Mufg Americas Hldgs Corp accumulated 0% or 988 shares. Fmr Ltd Co holds 0.01% or 4.40 million shares in its portfolio. Geneva Advsr Llc has invested 0.03% of its portfolio in Xencor Inc (NASDAQ:XNCR).
Insider Transactions: Since April 7, 2016, the stock had 0 insider buys, and 18 selling transactions for $8.24 million net activity. $596,523 worth of Xencor Inc (NASDAQ:XNCR) shares were sold by Dahiyat Bassil I. The insider STAFFORD JOHN S III sold $2.10M. Foster Paul A sold $20,123 worth of Xencor Inc (NASDAQ:XNCR) on Tuesday, June 28. The insider Baracchini Edgardo Jr sold $18,875. On Thursday, August 11 the insider CARTER BRUCE L A sold $77,074. Desjarlais John R sold 16,294 shares worth $354,065.
More recent Xencor Inc (NASDAQ:XNCR) news were published by: Fool.com which released: “This Caused Xencor Inc.’s Stock to Jump 11.6% in August” on September 10, 2016. Also Fool.com published the news titled: “Why Xencor Inc’s Shares Are Skyrocketing Today” on June 28, 2016. Prnewswire.com‘s news article titled: “Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195” with publication date: September 15, 2016 was also an interesting one.
XNCR Company Profile
Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company’s segment is related to the development of pharmaceutical products. The Firm uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company’s clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. The Company’s oncology product candidates are in preclinical stage, which include XmAb14045 for the treatment of acute myeloid leukemia (AML) and XmAb13676 for B-cell malignancy. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 (MOR208), an antibody drug candidate, and XmAb13551, a bispecific CD38 x CD3 preclinical candidate.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.